Blockchain technology is essentially a decentralized database maintained by relevant parties and has been widely used in various scenarios such as logistics and finance. In terms of applications in the medical field, it is becoming more and more important because the patient's symptoms may be related to a certain vaccine. Whether the patient has been vaccinated with this vaccine will lead to different diagnostic results by the doctor. However, in the current vaccination environment of many regions, the vaccination record (VR) can only be kept in the patient's vaccination booklet, which is easy to lose or destroy. Therefore, the doctor needs to retrieve the patient's VR through a centralized database maintained by the government, which is time-consuming and will increase the medical risk. This study proposes a traceable blockchain-based vaccination record storage and sharing system. In the proposed system, the patient gets the vaccination at any legal clinic and the VR can be saved accompanied by the signature into the blockchain center, which ensures traceability. When the patient visits the hospital for treatment, the doctor can obtain the detail of the VR from the blockchain center and then make a diagnosis. The security of the proposed system will be protected by the programmed smart contracts. Through mutual authentication, our system can also provide and guarantee data integrity and nonrepudiation. Moreover, the proposed system has resistance to replay and man-in-the-middle attacks, and the performance is good.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926549 | PMC |
http://dx.doi.org/10.1155/2022/2211065 | DOI Listing |
Braz J Microbiol
January 2025
Interdisciplinary Group of Virology and Immunology, Faculty of Medicine, Federal University of Rio Grande (FURG), Rio Grande, RS, Brazil.
COVID-19 caused a public health emergency, which instituted a global effort to develop vaccines using different platforms, such as basic types and new-generation vaccines. Considering the importance of vaccination in preventing the severity of infectious diseases and the success in developing and approving vaccines against COVID-19 in record time, it is essential to learn about the characteristics of these vaccines. This study aimed to conduct a structured, systematic review following the PRISMA guideline, to analyze the general characteristics of vaccines approved globally for use against COVID-19.
View Article and Find Full Text PDFBackground: With the world population aging, the number of individuals living with dementia is expected to increase significantly. Vaccination against herpes zoster (HZ) with the live-attenuated zoster vaccine (ZVL) was associated with a lower risk of being diagnosed with dementia in previous studies. We aimed to determine whether the recombinant zoster vaccine (RZV) immunization is also associated with a reduced risk of dementia diagnosis.
View Article and Find Full Text PDFBackground: Using a unique natural randomization, we have recently provided evidence from Welsh electronic health record data that herpes zoster (HZ) vaccination caused a reduction in new dementia diagnoses over a seven-year period. This study aimed to determine whether eligibility for HZ vaccination also caused a reduction in deaths due to dementia in England and Wales over a nine-year follow-up period.
Methods: Adults who had their 80 birthday shortly before September 1 2013 were ineligible for free HZ vaccination and remained ineligible for life, whereas those who had their 80 birthday shortly after September 1 2013 (i.
Background: The number people living with Alzheimer's disease and related dementias is expected to triple by 2050, contributing to decreased quality of life, increased medical care utilization, and additional burden on an already stressed primary care system. Many clinicians lack confidence to assess, diagnose and manage cognitive impairment (CI), and more than 50% of patients with CI are undiagnosed. A tool to better identify patients at risk of CI could lead to earlier detection and diagnosis in primary care.
View Article and Find Full Text PDFCan Commun Dis Rep
January 2025
Public Health Agency of Canada, Ottawa, ON.
Background: Availability of new vaccines for adults has increased interest in understanding Canada's respiratory syncytial virus (RSV) burden in older adults and adults considered at high risk of severe infection.
Objective: To characterize the burden of RSV disease in Canada by joint analysis of the published literature and hospitalization data from a healthcare administrative database.
Methods: Electronic databases of published literature were searched to identify studies and systematic reviews reporting data on outpatient visits, hospitalizations, intensive care unit (ICU) admissions and deaths associated with RSV infection in adults.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!